Iksuda signs licence agreement with Femtogenix for solid tumours
Iksuda Therapeutics and Femtogenix have signed a licensing agreement for antibody-drug conjugates.
Read More
Tag: Antibody-Drug Conjugates
UK firms link to develop ADCs for cancer
UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers.
Read More
Glythera launches Innovate UK-funded ADC project
UK biotech Glythera has announced the launch of a £1 million Innovate UK grant-funded project to develop next-generation antibody drug conjugates (ADCs) for difficult-to-treat tumours.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
